Osteoporosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Osteoporosis Market Outlook

Thelansis’s “Osteoporosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteoporosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Osteoporosis Overview

Osteoporosis is a debilitating skeletal disease characterized by the degradation of bone tissue microarchitecture and the loss of bone mass. This condition significantly increases bone fragility, making individuals more susceptible to fractures. The intricate process of bone turnover, normally a delicate balance between resorption and formation, is disrupted in osteoporosis. Osteoclasts play a role in bone removal through acidification and proteolytic digestion, while osteoblasts contribute by secreting osteoids into the resorption cavity. Postmenopausal women face a heightened risk of osteoporosis due to a rapid increase in bone turnover, persisting for up to 40 years after the cessation of ovarian function, leading to progressive bone loss. A myriad of factors contribute to the development of osteoporosis, including smoking, low body mass index, inadequate nutrition, vitamin D deficiency, low dietary calcium intake, aging, gender, hormonal changes, previous fractures, family history of osteoporosis, menopause, certain medications, and other underlying health conditions. In the United States, the impact of osteoporosis is substantial, affecting approximately 10 million people aged over 50, with an additional 34 million individuals at risk. Early detection and timely treatment of osteoporosis yield positive outcomes. However, if left untreated, this condition can result in chronic pain and an increased risk of fractures. Mitigating the risk of osteoporosis involves:

• Adopting preventive measures such as using bisphosphonates.
• Engaging in regular exercise.
• Maintaining a calcium-rich diet.

These interventions contribute to bone health and play a crucial role in reducing the overall burden of osteoporosis on individuals and the healthcare system.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: